Cue Biopharma, Inc. Total Liabilities
Cue Biopharma, Inc. (CUE) had Total Liabilities of $28.40 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-14
- 2026-06-30: Liabilities $28.40M.
- 2026-03-31: Liabilities $9.27M.
- 2025-12-31: Liabilities $15.78M.
- 2025-09-30: Liabilities $18.40M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $28.40M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $9.27M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $15.78M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $18.40M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $22.55M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $15.67M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $14.69M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $19.44M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $20.71M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $23.91M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $24.45M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $26.22M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $27.16M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $26.66M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $25.60M 10-K · filed 2024-03-28 | $25.60M 10-K · filed 2023-03-21 |
| 2022-09-30 | $25.54M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $24.99M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $26.03M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $17.91M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $15.36M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $16.76M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $19.05M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $20.62M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $19.06M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $21.20M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $15.41M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $17.02M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $18.19M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $21.48M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $20.45M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $11.39M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $5.18M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $3.88M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $4.08M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $5.35M 10-K · filed 2019-03-14 | $5.35M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |